These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17640305)

  • 21. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody.
    Stockmeyer B; Schiller M; Repp R; Lorenz HM; Kalden JR; Gramatzki M; Valerius T
    Br J Haematol; 2002 Sep; 118(4):959-67. PubMed ID: 12199773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement activation determines the therapeutic activity of rituximab in vivo.
    Di Gaetano N; Cittera E; Nota R; Vecchi A; Grieco V; Scanziani E; Botto M; Introna M; Golay J
    J Immunol; 2003 Aug; 171(3):1581-7. PubMed ID: 12874252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
    Kohrt HE; Thielens A; Marabelle A; Sagiv-Barfi I; Sola C; Chanuc F; Fuseri N; Bonnafous C; Czerwinski D; Rajapaksa A; Waller E; Ugolini S; Vivier E; Romagné F; Levy R; Bléry M; André P
    Blood; 2014 Jan; 123(5):678-86. PubMed ID: 24326534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. slan
    Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
    Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of the antibody-dependent tumoricidal activity of human monocytes by human monocytic colony-stimulating factor.
    Suzu S; Yanai N; Saito M; Kawashima T; Kasahara T; Saito M; Takaku F; Motoyoshi K
    Jpn J Cancer Res; 1990 Jan; 81(1):79-84. PubMed ID: 2108950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
    Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
    Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of macrophage colony-stimulating factor on macrophages and their related cell populations in the osteopetrosis mouse defective in production of functional macrophage colony-stimulating factor protein.
    Umeda S; Takahashi K; Shultz LD; Naito M; Takagi K
    Am J Pathol; 1996 Aug; 149(2):559-74. PubMed ID: 8701995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis.
    Metelitsa LS; Gillies SD; Super M; Shimada H; Reynolds CP; Seeger RC
    Blood; 2002 Jun; 99(11):4166-73. PubMed ID: 12010822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor.
    Munn DH; Cheung NK
    J Exp Med; 1990 Jul; 172(1):231-7. PubMed ID: 2193096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.
    Stockmeyer B; Elsässer D; Dechant M; Repp R; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
    J Immunol Methods; 2001 Feb; 248(1-2):103-11. PubMed ID: 11223072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Granulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantation.
    Nagler A; Shur I; Barak V; Fabian I
    Leuk Res; 1996 Aug; 20(8):637-43. PubMed ID: 8913316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.
    Masucci G; Wersäll P; Ragnhammar P; Mellstedt H
    Cancer Immunol Immunother; 1989; 29(4):288-92. PubMed ID: 2665935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor.
    Wallace PK; Romet-Lemonne JL; Chokri M; Kasper LH; Fanger MW; Fadul CE
    Cancer Immunol Immunother; 2000 Nov; 49(9):493-503. PubMed ID: 11092616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis.
    Iwahashi M; Yamamura M; Aita T; Okamoto A; Ueno A; Ogawa N; Akashi S; Miyake K; Godowski PJ; Makino H
    Arthritis Rheum; 2004 May; 50(5):1457-67. PubMed ID: 15146415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF.
    Schmid I; Baldwin GC; Jacobs EL; Isacescu V; Neagos N; Giorgi JV; Glaspy JA
    Cytometry; 1995 Jun; 22(2):103-10. PubMed ID: 7587740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages.
    Keler T; Wallace PK; Vitale LA; Russoniello C; Sundarapandiyan K; Graziano RF; Deo YM
    J Immunol; 2000 Jun; 164(11):5746-52. PubMed ID: 10820252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.